Your session is about to expire
← Back to Search
Androgen Deprivation Therapy for Prostate Cancer
Study Summary
This trial will investigate the effects of degarelix on human prostate cancer cells.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 3 trial • 645 Patients • NCT00079001Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My biopsy shows at least 2 samples with cancer longer than 3mm.My prostate cancer is aggressive (Gleason score 7 or higher).I have had blood clots or a stroke but am considered fit for surgery.I am planning to have or have had a major prostate surgery at MSKCC.My prostate cancer diagnosis was confirmed with a biopsy showing 3 or more positive cores.I have enough biopsy tissue available for analysis.You cannot take any other experimental drugs while participating in this study.My cancer is not adenocarcinoma but another type.I stopped taking dutasteride at least 4 weeks before my treatment or surgery.I have undergone chemotherapy.I have taken saw palmetto for my cancer within a week of receiving degarelix or before surgery.I have received radiation therapy for prostate cancer.I do not have any ongoing infections or illnesses.I have not used hormonal therapies like antiandrogens for my condition.I agree to use contraception during and for 3 months after the study.My testosterone level is above 100 ng/dL.I have been on hormone therapy for prostate cancer for 1-6 months before surgery.I am mostly independent and can care for myself.
- Group 1: Untreated patients degarelix injection occur at days 4± 1
- Group 2: Untreated patients degarelix injection occur at days and 7± 1.
- Group 3: treated patients with androgen deprivation
- Group 4: Untreated patients degarelix injection occur at days 14±1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you elucidate other investigations that have explored androgen deprivation therapy?
"At the moment, 31 medical trials are actively investigating androgen deprivation therapy. Of those31 studies, 8 are in their final phase of clinical trial testing. While mostly centred around Los Angeles, 1481 other locations across the nation have ongoing research for this treatment."
Is this research unprecedented in its field?
"Since 2012, experiments into androgen deprivation therapy have been ongoing. The original research was backed by Ferring Pharmaceuticals in 2012 and completed with 41 participants; after that successful trial it received the necessary approval for medicinal use. Presently, 31 live trials are scattered across 563 cities within 14 countries."
Are there any slots left to participate in this experiment?
"According to clinicaltrials.gov, this trial is not accepting participants at the moment. This experiment was initially listed on February 1st 2012 and last updated on February 28th 2022. However, there are over 1300 other trials currently recruiting volunteers in various locations throughout the world."
What is the current enrollment capacity for this research endeavor?
"This investigation has reached its recruitment limit for now; the initial post date was February 1st 2012, and it has been revised as recently as 28th of February 2022. Notwithstanding, there are currently 1321 trials that involve persons with prostate cancer searching for subjects and 31 experiments concerning Androgen Deprivation Therapy looking to enroll participants."
Share this study with friends
Copy Link
Messenger